Skip to main content
Erschienen in: Forensic Science, Medicine and Pathology 1/2019

29.11.2018 | Case Report

Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction

verfasst von: Rhome L. Hughes

Erschienen in: Forensic Science, Medicine and Pathology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Kratom is a plant with dose-dependent mixed stimulant and opioid properties whose pharmacologic characteristics and social impact continue to be described. The main active isolate of kratom is mitragynine, an indole-containing alkaloid with opioid-like effects. Kratom toxicity and kratom-associated fatalities have been described, including those in association with additional drugs. In this paper we describe the case of a 27-year-old man who was found deceased with a toxic blood concentration of quetiapine in conjunction with the qualitative presence of mitragynine. Investigative and autopsy findings suggested perimortem hyperthermia and seizure-like activity. Kratom toxicity and kratom-associated fatalities are being increasingly reported. Experiments with kratom extracts have shown inhibitory effects upon hepatic CYP enzymes, leading to previous speculation of the potential for clinically significant interactions between kratom and a wide array of medications. Herein is described a fatal case of quetiapine toxicity complicated by mitragynine use. The potential ability of mitragynine to alter the pharmacokinetics of a prescription medication via inhibition of its hepatic metabolism is discussed.
Literatur
1.
Zurück zum Zitat Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9.PubMedPubMedCentral Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9.PubMedPubMedCentral
2.
Zurück zum Zitat Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–9.PubMed Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–9.PubMed
3.
Zurück zum Zitat Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17:580.CrossRef Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17:580.CrossRef
5.
Zurück zum Zitat Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355–7.CrossRef Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355–7.CrossRef
6.
Zurück zum Zitat Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49–52.PubMed Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49–52.PubMed
8.
Zurück zum Zitat Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61–3.CrossRef Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61–3.CrossRef
9.
Zurück zum Zitat Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–7.CrossRef Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–7.CrossRef
10.
Zurück zum Zitat Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.CrossRef Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.CrossRef
11.
Zurück zum Zitat Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424–6.CrossRef Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424–6.CrossRef
12.
Zurück zum Zitat Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008. Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008.
13.
Zurück zum Zitat Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010. Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010.
14.
Zurück zum Zitat Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785–91.CrossRef Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785–91.CrossRef
15.
Zurück zum Zitat Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015. Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015.
16.
Zurück zum Zitat Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599–602.CrossRef Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599–602.CrossRef
17.
Zurück zum Zitat Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.CrossRef Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.CrossRef
18.
Zurück zum Zitat Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254–8.CrossRef Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254–8.CrossRef
19.
Zurück zum Zitat Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58–69.CrossRef Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58–69.CrossRef
20.
Zurück zum Zitat Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241–6. Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241–6.
21.
Zurück zum Zitat Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMed Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMed
22.
Zurück zum Zitat Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187–211.CrossRef Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187–211.CrossRef
23.
Zurück zum Zitat Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances – stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220–6.CrossRef Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances – stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220–6.CrossRef
24.
Zurück zum Zitat Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–20.CrossRef Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–20.CrossRef
Metadaten
Titel
Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction
verfasst von
Rhome L. Hughes
Publikationsdatum
29.11.2018
Verlag
Springer US
Erschienen in
Forensic Science, Medicine and Pathology / Ausgabe 1/2019
Print ISSN: 1547-769X
Elektronische ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-018-0049-9

Weitere Artikel der Ausgabe 1/2019

Forensic Science, Medicine and Pathology 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie